Welcome to our dedicated page for Ocular Therapeut news (Ticker: OCUL), a resource for investors and traders seeking the latest updates and insights on Ocular Therapeut stock.
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical innovator developing sustained-release therapies for retinal diseases and ocular conditions. This page serves as the definitive source for company news, providing investors and professionals with timely updates on clinical advancements, regulatory developments, and corporate milestones.
Access press releases, earnings reports, and analysis of key events impacting OCUL's trajectory. Our curated collection includes updates on AXPAXLI™ clinical trials for wet AMD, DEXTENZA® commercial performance, and pipeline progress across glaucoma and diabetic retinopathy therapies. Discover how the company's proprietary hydrogel platform addresses treatment challenges in ophthalmology.
Bookmark this page for streamlined access to OCUL's latest FDA submissions, partnership announcements, and financial disclosures. Stay informed about developments influencing both near-term performance and long-term growth in ocular therapeutics.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced its participation at the ARVO Annual Meeting from April 23-27, 2023, showcasing significant clinical and pre-clinical data related to its innovative hydrogel therapies for eye diseases. Chief Medical Officer Rabia Gurses-Ozden emphasized the importance of their drug delivery platform, particularly for conditions affecting the front and back of the eye. Key presentations include updates on the OTX-TKI, an axitinib intravitreal implant for wet AMD, showing interim results from ongoing trials. Other topics involve OTX-TIC for glaucoma and advancements in their early-stage gene therapy pipeline. The presentations aim to highlight the efficacy and safety of their products, positioning Ocular Therapeutix for future growth.
Ocular Therapeutix (NASDAQ:OCUL) reported its financial results for Q4 and the full year 2022, achieving total net revenue of $51.5 million, an 18% increase from the previous year. Fourth-quarter net revenue was $14.1 million, also up 18%. The company highlighted progress in its clinical pipeline, notably with interim data from a Phase 1 trial of OTX-TKI for wet AMD, showing a 73% rescue-free rate maintained at 10 months. DEXTENZA, another key product, generated $13.9 million in Q4 revenue, marking a 17% quarter-over-quarter growth. The company forecasts DEXTENZA revenue for 2023 between $55 and $60 million, a 10% to 20% year-over-year growth.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced that its President and CEO, Antony Mattessich, will participate in a fireside chat at Cowen’s 43rd Annual Healthcare Conference on March 7, 2023, at 1:30 PM EST. Investors wishing to meet with Ocular Therapeutix management during the conference should contact their Cowen representative. A live webcast of the presentation will be available on the company’s website.
The company focuses on developing innovative therapies for eye diseases and conditions, including DEXTENZA®, an FDA-approved corticosteroid. It is also advancing multiple assets in clinical trials for various eye conditions.
Ocular Therapeutix (NASDAQ: OCUL) will announce its fourth quarter and year-end financial results on March 6, 2023, after market close. CEO and management will discuss these results in a conference call at 4:30 PM ET. Investors can access the live webcast through a provided link. Ocular Therapeutix specializes in innovative therapies for eye conditions, with its flagship product, DEXTENZA®, an FDA-approved corticosteroid for treating ocular inflammation. The company is also developing other treatments currently in various clinical trial phases.
Ocular Therapeutix (NASDAQ:OCUL) announced promising interim results from its U.S. Phase 1 clinical trial of OTX-TKI, an axitinib hydrogel implant for treating wet age-related macular degeneration (wet AMD). At the 10-month mark, 73% of subjects remained rescue-free, demonstrating an impressive 92% reduction in treatment burden. The data showed that OTX-TKI was generally well tolerated, with no serious adverse events reported. Best corrected visual acuity (BCVA) and central subfield thickness (CSFT) measures were comparable to those receiving aflibercept. The company plans to meet with the FDA to discuss future trials and potential strategic alliances.
Ocular Therapeutix (NASDAQ:OCUL) reported a strong performance for DEXTENZA, with fourth quarter 2022 net product revenue estimated at $13.6 million, marking a growth of 14% from the previous quarter and 11% year-over-year. For the full year, revenue is estimated at $50.2 million, reflecting a 20% increase from 2021. The company is advancing clinical trials for OTX-TKI (for wet AMD and diabetic retinopathy) and OTX-TIC (for glaucoma), with key data expected in 2023.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced its participation in several upcoming conferences. These include the Jefferies London Healthcare Conference on
Ocular Therapeutix (OCUL) reported positive interim results from its Phase 1 trial of OTX-TKI for wet AMD, with 80% of subjects rescue-free at 6 months. The company plans to initiate a Phase 1 trial for diabetic retinopathy in Q1 2023 and a Phase 2/3 trial for wet AMD in Q3 2023. DEXTENZA revenue reached $11.9 million in Q3, with annual guidance revised to $48-$52 million, reflecting 10%-20% growth. The company reported a net loss of $24.2 million, leading to a loss per share of $(0.31). Cash and equivalents stood at $121 million, indicating sufficient funds through 2023.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) will report its third quarter financial results for the period ended September 30, 2022, after market close on November 7, 2022. A live conference call and webcast will follow at 4:30 p.m. ET to discuss these results and provide a business update. Key developments include FDA-approved DEXTENZA® for ocular conditions and ongoing clinical trials for multiple innovative drug candidates targeting various eye diseases, including wet AMD and glaucoma.
Ocular Therapeutix (NASDAQ:OCUL) announced interim results from its U.S. Phase 1 trial of OTX-TKI, an axitinib hydrogel implant for treating wet AMD. The trial involved 21 subjects and showed OTX-TKI was well tolerated with no serious drug-related adverse events. At 7 months, subjects demonstrated stable best corrected visual acuity and central subfield thickness. Notably, 80% were rescue-free for 6 months and 73% for 7 months. The company plans to discuss next steps with the FDA and may initiate a Phase 2 trial in Q3 2023.
